Archive for the ‘Cell Therapy’ Category

Adler Footcare - Stem Cell Therapy
Backed by years of research, thousands of happy patients, and faster healing time is the latest in ethical stem cell treatments for foot pain offered at Adle...

By: Adler Footcare

See original here:
Adler Footcare - Stem Cell Therapy - Video

Stem Cell Therapy | stem cell mobilization gcsf
http://www.arthritistreatmentcenter.com Another breakthrough in stem cell science and we have lab rats to thank for it next Osteoarthritis in rats responds to stem cell mobilization therapy...

By: Nathan Wei

More here:
Stem Cell Therapy | stem cell mobilization gcsf - Video

Chicago, Illinois (PRWEB) October 30, 2014

On October 26th at the Mid American Regenerative and Cellular Medicine Showcase in Chicago, leading applied stem cell research scientist Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna presented talks on New Techniques for Enhancing Stem Cell Therapy Effectiveness and Orthopedic Surgical Applications For Stem Cells.

Dr. Riordan focused on historical medical uses of amniotic membrane and the properties of AlphaGEMS that include: wound healing; inflammation and pain reduction; fibrosis risk reduction; growth factor source; adhesion reduction; regeneration support and stem cell enhancement, specifically regarding the mesenchymal stem cells contained within BMAC.

Dr. McKenna discussed the latest applications of BMAC stem cells in orthopedic surgeries like anterior cruciate ligament (ACL) reconstruction and how BMAC injections can virtually eliminate infection risk, reduce complications, increase graft strength, reduce post-surgical inflammation and significantly reduce recovery time. Dr. McKenna also talked about how bone marrow can now be safely and relatively painlessly harvested using his patented BioMAC catheter under local, not general anesthesia.

Dr. Riordan and Dr. McKenna are co-founders of the Riordan-McKenna Institute (RMI), which will be opening soon in Southlake, Texas. RMI will specialize in regenerative orthopedics including non-surgical stem cell therapy and stem cell-enhanced surgery using bone marrow aspirate concentrate (BMAC) and AlphaGEMS amniotic tissue product.

Other noteworthy speakers in attendance included: Paolo Macchiarini, MD-PhD, Arnold Caplan, PhD and Mark Holterman, MD-PhD. Dr. Macchiarini and Dr. Holterman are well known for their work on the first stem cell trachea transplant. Dr. Caplan discovered the mesenchymal stem cell and is commonly referred to as the father of the mesenchymal stem cell.

About Neil Riordan PhD

Dr. Riordan is the co-founder of the Riordan-McKenna Institute (RMI), which will be opening soon in Southlake, Texas. RMI will specialize in regenerative orthopedics including non-surgical stem cell therapy and stem cell-enhanced surgery using bone marrow aspirate concentrate (BMAC) and AlphaGEMS amniotic tissue product.

Dr. Riordan is founder and chief scientific officer of Amniotic Therapies Inc. (ATI). ATI specializes in amniotic tissue research and development. Its current product line includes AlphaGEMS and AlphaPATCH amniotic tissue-based products.

Dr. Riordan is the founder and chairman of Medistem Panama, Inc., (MPI) a leading stem cell laboratory and research facility located in the Technology Park at the prestigious City of Knowledge in Panama City, Panama. Founded in 2007, MPI stands at the forefront of applied research on adult stem cells for several chronic diseases. MPI's stem cell laboratory is ISO 9001 certified and fully licensed by the Panamanian Ministry of Health. Dr. Riordan is the founder of Stem Cell Institute (SCI) in Panama City, Panama (est. 2007).

Read more from the original source:
Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid ...

JACKSON, Tenn. (PRWEB) October 30, 2014

Dr. Roy Schmidt and the staff of the Pain Specialist Center will host a free seminar and question-and-answer session about regenerative medicine on Tuesday, Nov. 11 at 6 p.m. Held at the clinic at 15 Stonebridge Blvd. in Jackson, the hour-long event will allow attendees to ask questions about stem cell therapy and platelet rich plasma therapy in a relaxed atmosphere. Guests also will have the chance to talk to individuals who have received regenerative medicine treatments, which focus on helping patients relieve pain by supporting the healing process.

Stem cell therapy focuses on delivering the patients own stem cells to parts of the body that are in need. After adipose tissue (comprised of fat cells) is taken from the patients body, it is made into a stem cell concentrate. That concentrate is injected at the focal point of pain or area that needs healing. Schmidt, who is certified to administer stem cell therapy, was trained by Bioheart Chief Scientific Officer Kristin Comella. Comella has been recognized as a national leader in stem cell therapy.

Platelet rich plasma (PRP) or platelet concentrates have been studied extensively since the 1990s. While similar products previously used in medicine (fibrin glue) were very expensive, PRP provides a cost-effective alternative. Plasma concentrates seek to help the body continue the healing process and strengthen the weakened tissue. It is often used for tendon problems, in addition to issues with ligaments, muscles, meniscus, cartilage, bone, wound and intervertebral discs. The supplemental role of hyperbaric oxygen therapy will be discussed at the event, also.

A board certified anesthesiologist, Schmidt has practiced pain management in the Jackson area for two decades. The Pain Specialist Center provides consultation and pain management services to patients suffering from chronic pain syndromes and terminal cancer pain. Individuals can learn more by going online to http://beyondpills.com, http://nopainmd.com and http://hyperbaricoxygentherapies.com, calling 731-660-2056 or e-mailing info(at)beyondpills(dot)com. Event information is on Facebook at http://www.facebook.com/PainSpecialistCenter.

Here is the original post:
Seminar on Regenerative Medicine Open to Public

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. They are found in multicellular organisms. In mammals, there are two broad types of stem cells: embryonic stem cells, which are isolated from the inner cell mass of blastocysts, and adult stem cells, which are found in various tissues. In adult organisms, stem cells and progenitor cells act as a repair system for the body, replenishing adult tissues. In a developing embryo, stem cells can differentiate into all the specialized cellsectoderm, endoderm and mesoderm (see induced pluripotent stem cells)but also maintain the normal turnover of regenerative organs, such as blood, skin, or intestinal tissues.

There are three known accessible sources of autologous adult stem cells in humans:

Stem cells can also be taken from umbilical cord blood just after birth. Of all stem cell types, autologous harvesting involves the least risk. By definition, autologous cells are obtained from one's own body, just as one may bank his or her own blood for elective surgical procedures.

Adult stem cells are frequently used in medical therapies, for example in bone marrow transplantation. Stem cells can now be artificially grown and transformed (differentiated) into specialized cell types with characteristics consistent with cells of various tissues such as muscles or nerves. Embryonic cell lines and autologous embryonic stem cells generated through Somatic-cell nuclear transfer or dedifferentiation have also been proposed as promising candidates for future therapies.[1] Research into stem cells grew out of findings by Ernest A. McCulloch and James E. Till at the University of Toronto in the 1960s.[2][3]

The classical definition of a stem cell requires that it possess two properties:

Two mechanisms exist to ensure that a stem cell population is maintained:

Potency specifies the differentiation potential (the potential to differentiate into different cell types) of the stem cell.[4]

In practice, stem cells are identified by whether they can regenerate tissue. For example, the defining test for bone marrow or hematopoietic stem cells (HSCs) is the ability to transplant the cells and save an individual without HSCs. This demonstrates that the cells can produce new blood cells over a long term. It should also be possible to isolate stem cells from the transplanted individual, which can themselves be transplanted into another individual without HSCs, demonstrating that the stem cell was able to self-renew.

Properties of stem cells can be illustrated in vitro, using methods such as clonogenic assays, in which single cells are assessed for their ability to differentiate and self-renew.[7][8] Stem cells can also be isolated by their possession of a distinctive set of cell surface markers. However, in vitro culture conditions can alter the behavior of cells, making it unclear whether the cells will behave in a similar manner in vivo. There is considerable debate as to whether some proposed adult cell populations are truly stem cells.

Embryonic stem (ES) cells are stem cells derived from the inner cell mass of a blastocyst, an early-stage embryo.[9] Human embryos reach the blastocyst stage 45 days post fertilization, at which time they consist of 50150 cells. ES cells are pluripotent and give rise during development to all derivatives of the three primary germ layers: ectoderm, endoderm and mesoderm. In other words, they can develop into each of the more than 200 cell types of the adult body when given sufficient and necessary stimulation for a specific cell type. They do not contribute to the extra-embryonic membranes or the placenta.

See the article here:
Stem cell - Wikipedia, the free encyclopedia

PUBLIC RELEASE DATE:

23-Oct-2014

Contact: Scott LaFee slafee@ucsd.edu 619-543-6163 University of California - San Diego @UCSanDiego

In a push to further speed clinical development of emerging stem cell therapies, Sanford Stem Cell Clinical Center at UC San Diego Health System was named today one of three new "alpha clinics" by the California Institute for Regenerative Medicine (CIRM), the state's stem cell agency.

The announcement, made at a public meeting in Los Angeles of the CIRM Governing Board, includes an award of $8 million for each of three sites. The other alpha grant recipients are the City of Hope hospital near Los Angeles and University of California, Los Angeles.

"A UC San Diego alpha clinic will provide vital infrastructure for establishing a comprehensive regenerative medicine clinical hub that can support the unusual complexity of first-in-human stem cell-related clinical trials," said Catriona Jamieson, MD, PhD, associate professor of medicine at UC San Diego School of Medicine, deputy director of the Sanford Stem Cell Clinical Center, director of the UC San Diego Moores Cancer Center stem cell program and the alpha clinic grant's principal investigator.

"The designation is essential in much the same manner that comprehensive cancer center status is an assurance of scientific rigor and clinical quality. It will attract patients, funding agencies and study sponsors to participate in, support and accelerate novel stem cell clinical trials and ancillary studies for a range of arduous diseases."

The alpha clinics are intended to create the long-term, networked infrastructure needed to launch and conduct numerous, extensive clinical trials of stem cell-based drugs and therapies in humans, including some developed by independent California-based investigators and companies. These trials are requisite before any new drug or treatment can be approved for clinical use.

The clinics will also emphasize public education to raise awareness and understanding of stem cell science in part to combat "stem cell tourism" and the marketing of unproven, unregulated and potentially dangerous therapies and help establish sustainable business models for future, approved stem cell treatments.

"Everything we do has one simple goal, to accelerate the development of successful treatments for people in need," said C. Randal Mills, PhD, CIRM president and CEO. "Stem cell therapies are a new way of treating disease; instead of managing symptoms, cellular medicine has the power to replace or regenerate damaged tissues and organs. And so we need to explore new and innovative ways of accelerating clinical research with stem cells. That is what we hope these alpha stem cell clinics will accomplish."

Go here to read the rest:
UC San Diego named stem cell 'alpha clinic'

Stem Cell Hair Therapy - Hair Regrowth Treatment using Adult Stem Cell from Luminesce
Do It Yourself - Stem Cell Hair Therapy : http://placesiana.com/stem-cell-hair-loss-therapy Imagine becoming a healthier, much younger, better looking you? Infused with a potent growth factor...

By: Sam Jeunesse

Read the rest here:
Stem Cell Hair Therapy - Hair Regrowth Treatment using Adult Stem Cell from Luminesce - Video

Dunmore, Pennsylvania (PRWEB) October 17, 2014

VCA Dunmore Animal Hospital is proud to announce the addition of Shannon Layne, DVM and her interest in stem cell therapy to their team. Credentialed in Regenerative Cell Therapy with Vet-Stem since January of 2011, Dr. Layne has proudly been treating pets with osteoarthritis and ligament injuries in north-east Pennsylvania with stem cell therapy for the last four years.

Dr. Layne graduated from North Carolina State University, College of Veterinary Medicine in 2010 and has taken a special interest in Regenerative Veterinary Medicine and stem cell therapy since. In contrast to widely used drug therapies for pain management, cell-based therapies (like stem cell therapy) can promote healing, reduce inflammation, and decrease pain. Dr Layne also offers traditional Chinese veterinary medicine including acupuncture and Chinese herbs if clients are interested in a more holistic approach.

Stem cells are regenerative cells that can differentiate into many tissue types (reducing pain and inflammation) thus helping to restore range of motion and regenerate tendon, ligament and joint tissues (Vet-Stem.com/science). In a study using Vet-Stem Regenerative Cell Therapy on dogs with osteoarthritis of the hip joint it was found that regenerative cell therapy (adipose-derived stem cells) decreases patient discomfort and increases patient functional ability.

Once Dr. Layne has identified a patient as a good candidate for stem cell therapy the procedure begins with a fatty tissue collection from the patient. The tissue sample is sent overnight to Vet-Stems lab in California for processing. Once processed the stem cells are extracted and fresh, injectable doses of the patients stem cells are sent overnight, back to Dr. Layne at VCA Dunmore Animal Hospital. Within 48hrs of collecting a fat sample from a patient Dr. Layne is able to inject stem cells into (arthritic or injured) affected areas and regeneration and healing can begin.

At VCA Dunmore Animal Hospital Dr. Layne will be practicing in an 8,800 square foot, state of the art facility that includes two extensive surgery suites. For more information on VCA Dunmore Animal Hospital please visit their website at http://www.vcahospitals.com/dunmore.

About Vet-Stem, Inc.

Since its formation in 2002, Vet-Stem, Inc. has endeavored to improve the lives of animals through regenerative medicine. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem pioneered the use of regenerative stem cells for horses, dogs, cats, and some exotics. In 2004 the first horse was treated with Vet-Stem Regenerative Cell Therapy for a tendon injury that would normally have been career ending. Ten years later Vet-Stem celebrated its 10,000th animal treated, and the success of establishing stem cell therapy as a regenerative medicine for certain inflammatory, degenerative, and arthritic diseases. As animal advocates, veterinarians, veterinary technicians, and cell biologists, the team at Vet-Stem tasks themselves with the responsibility of discovering, refining, and bringing to market innovative medical therapies that utilize the bodys own healing and regenerative cells.

For more information about Vet-Stem and Regenerative Veterinary Medicine visit http://www.vet-stem.com or call 858-748-2004.

More here:
Shannon Layne, DVM and VCA Dunmore Animal Hospital Now Offer Stem Cell Therapy to Pet Patients in Pain

Knee arthritis 2.5 years after stem cell therapy by Harry Adelson, N.D.
Janet discusses her outcome three and a half years after bone marrow stem cell therapy by Dr Harry Adelson for her arthritic knees http://www.docereclinics.com.

By: Harry Adelson, N.D.

Read more here:
Knee arthritis 2.5 years after stem cell therapy by Harry Adelson, N.D. - Video

By C. Rajan, contributing writer

The U.S. FDA has just granted BrainStorm Cell Therapeutics novel stem cell therapy, NurOwn, Fast Track status for the treatment of amyotrophic lateral sclerosis (ALS), the company announced via press release.

"We are pleased that the FDA has granted Fast Track status for NurOwn as this will allow us greater and more frequent dialogue with the Agency as we continue the development of this ground-breaking cell therapy for the treatment of ALS," said Tony Fiorino, MD, PhD, CEO of BrainStorm. "We expect Fast Track designation, which recognizes the potential of NurOwn as to address an unmet medical need in ALS, to help speed and improve our development program."

Israeli biotech company BrainStorm is developing novel adult stem cell technologies for neurodegenerative diseases, such as ALS. The company licensed the exclusive rights to the NurOwn technology from Ramot, the technology transfer company of Tel Aviv University.

NurOwn is a personalized stem cell product made from autologous mesenchymal stem cells. These adult stem cells are obtained from the patients bone marrow and are induced to secrete neurotrophic factors, which are growth factors that can stimulate the survival and maintenance of neurons that degenerate in neurologic disorders.

NurOwn is currently being studied in randomized, double-blind, placebo-controlled phase 2 clinical trials in ALS patients in both Israel and the U.S. Reuters reports that the last patient visit has been completed in the phase 2a clinical trial in Jerusalem. The company expects to release final results of the study by the end of this year. The U.S. arm of the Phase 2 study is being conducted at three sites in the U.S., and is expected to be wrapped up in early 2015.

The FDA's Fast Track program aims to speed up the development of new drugs and biologics in order to get them to patients suffering from serious, unmet medical needs. The Fast Track designation will allow BrainStorm Cell to submit an NDA on a rolling basis and will grant the company more communication and support from FDA during the development process.

ALS, also known as Lou Gehrig's disease, is a rapidly progressive neurological disease that results in death within 2 to 5 years of diagnosis in most cases, and less than 20 percent of patients live more than 5 years after onset of symptoms. The relatively rare condition affects about 2 persons in every 100,000, with approximately 5,600 new cases diagnosed every year in the U.S, according to the ALS Association.

There is no cure for the disease to date, although the only approved ALS drug, Riluzole, has demonstrated its ability to extend survival by at least a few months.

Visit link:
Stem Cell Therapy For ALS Gets FDA's Fast Track Designation

PUBLIC RELEASE DATE:

14-Oct-2014

Contact: David McKeon DMcKeon@nyscf.org 212-365-7440 New York Stem Cell Foundation @nyscf

NEW YORK, NY (October 14, 2014) The New York Stem Cell Foundation (NYSCF) announced today that Marius Wernig, PhD, Associate Professor in the Institute for Stem Cell Biology and Regenerative Medicine and the Department of Pathology at Stanford University School of Medicine, is the 2014 recipient of the NYSCF Robertson Stem Cell Prize, which has been awarded since 2011 for extraordinary achievements in translational stem cell research by a young scientist.

Dr. Wernig and his team discovered that human skin cells can be converted directly into functional neurons, termed induced neuronal (iN) cells, in a period of four to five weeks with the addition of just four proteins.

"Dr. Wernig's groundbreaking research has the potential to accelerate all research on devastating neurodegenerative diseases," said Susan L. Solomon, CEO and Co-founder of NYSCF. "His work can impact and accelerate research on multiple sclerosis, Alzheimer's disease, and autism among many other conditions."

At Stanford, Dr. Wernig focuses on using induced pluripotent stem (iPS) cells and iN cells for disease modeling and as potential cellular therapy. This new technique transformed the field of cellular reprogramming by eliminating the need to first create iPS cells, making it easier to generate patient or disease-specific neurons. These cell types hold tremendous therapeutic and translational relevance for patients around the world. Potential applications range from replacing damaged brain tissue to repairing the myelinating nerves lost in multiple sclerosis to identifying novel drugs and treatments for a range of neurological diseases.

In addition to his recent scientific achievements, Dr. Wernig was part of the inaugural class of NYSCF Robertson Stem Cell Investigators in 2010, and is the first NYSCF Robertson Investigator to receive the NYSCF Robertson Stem Cell Prize.

"I am delighted that Dr. Wernig is being recognized with this year's NYSCF Robertson Prize for his important research that has opened entirely new avenues for studying brain diseases. The NYSCF Robertson Prize was created to acknowledge the most important work being down by young stem cell scientists and I am thrilled to see a NYSCF Robertson Investigator go on to receive NYSCF Robertson Prize," said Julian Robertson, whose foundation underwrites the $200,000 prize. The terms of the prize require that the $200,000 stipend be used, at the recipients' discretion, to further support their research.

The NYSCF Robertson Stem Cell Prize will be presented to Dr. Wernig at a ceremony in New York City by Susan L. Solomon on October 14th.

More here:
Marius Wernig receives New York Stem Cell Foundation's Robertson Stem Cell Prize

96 Year Old Women gets Stem Cell Therapy
96 Year Old Women who suffered from Osteoarthritis uses Stem Cells and no longer needs to use her walker. Dr. Lox | http://www.drloxstemcells.com | 844-440-8503.

By: Dr. Lox

See the original post:
96 Year Old Women gets Stem Cell Therapy - Video

Stem Cell Therapy For Hair - Stem Cell Therapy For Hair Loss
Stem Cell Therapy For Hair - Stem Cell Therapy For Hair Loss http://goo.gl/4AKoXG Drained of staring at your balding pate every single morning? Seeking helpful and trusted means of eliminating...

By: Amit Kumar

More here:
Stem Cell Therapy For Hair - Stem Cell Therapy For Hair Loss - Video

Cookie - 9 Year Old Lab - Before Stem Cell Therapy
Watch the amazing after video here: https://www.youtube.com/watch?v=SRPO4OHKKlA.

By: Newman Veterinary Centers

Here is the original post:
Cookie - 9 Year Old Lab - Before Stem Cell Therapy - Video

Stem Cell Therapy Walkthrough - Watch This Before Calling Or Scheduling
http://www.innovationsstemcellcenter.com Call: 214.420.7970 Facebook: https://www.facebook.com/innovationsmedical Twitter: https://twitter.com/dallasdrj Instagram: http://instagram.com/drbilljo...

By: dallasdrj

View post:
Stem Cell Therapy Walkthrough - Watch This Before Calling Or Scheduling - Video

Adult Stem Cell Therapy Today: The Future is Here
Leslie Miller, M.D., F.A.C.C. and Okyanos Chief Science Officer, gives an overview of the benefits of adult stem cell therapy for severe heart disease patients. Okyanos provides Cardiac Cell...

By: Okyanos Heart Institute

Go here to read the rest:
Adult Stem Cell Therapy Today: The Future is Here - Video

The Goal of Cardiac Stem Cell Therapy at Okyanos
Leslie Miller, M.D., F.A.C.C. and Okyanos Chief Science Officer, describes the goal of treating congestive heart failure and coronary artery disease patients with their own fat-derived stem...

By: Okyanos Heart Institute

More:
The Goal of Cardiac Stem Cell Therapy at Okyanos - Video

Stem Cell Therapy for Hair Growth
Award winning dr devesh clinic is pioneer in stem cell hair restoration in india. visit @ http://www.drdevesh.in http://www.hairtransplantsdelhi.in facebook page- prp hair india http://www.fb.com/biofuehairtransplant.

By: dr.devesh aggarwal

Go here to read the rest:
Stem Cell Therapy for Hair Growth - Video

Natural Stem Cell Therapy Revealed - with David Wolfe
For more information please visit: http://www.womenswellnessconference.com/2014/womens-wellness-conference-2014-webcast/

By: Longevity Now

Follow this link:
Natural Stem Cell Therapy Revealed - with David Wolfe - Video

China tests stem cell therapy for heart disease
Monday marks World Heart Day. One of the most serious conditions is Chronic Heart Disease. It has no cure to date, but in China, scientists are hoping to find one, using stem-cell technology.

By: CCTV America

Continue reading here:
China tests stem cell therapy for heart disease - Video

Stem Cell Therapy The Aspen Institute for Anti Aging Regenerative Medicine

By: Cupio Media

Originally posted here:
Stem Cell Therapy The Aspen Institute for Anti Aging & Regenerative Medicine - Video

About cell therapy

Cell therapy is a new official direction in medicine, based on the use of regenerative potential of the adult stem cells, aimed at the treatment of a variety of serious diseases, rehabilitation of patients after injuries and fighting with the premature signs of aging. Stem cells are also considered to be the promising biological material for the creation of the prosthetic heart valves, blood vessels, trachea, they are also used as the unique biofiller for the reconstitution of bone defects and other purposes of the plastic and reconstructive surgery.

The scientists explain the regenerative mechanism of action of stem cells both by their ability to transform into the cells of blood, liver, myocardium, bone, cartilage or nervous tissue and thus restore damaged organs and also by the reovery of the functional activity of the other cells (through the so-called paracrine type) by means of the production of a variety of growth factors.

For clinical purposes, in most cases stem cells are obtained from the bone marrow and cord blood, it is also known that the amount of stem cells, sufficient for treatment, can be isolated from the peripheral blood of an adult person, but after pre-stimulation of hematopoiesis. In recent years there is an increasing number of reports worldwide on the clinical application of stem cells, derived from the placenta, adipose tissue, umbilical cord tissue, amniotic fluid, and even pulp of the milk teeth. Depending on the disease, age and condition of the patient, one or another source of stem cells may be preferred. Hematopoietic (blood-forming) stem cells are used for more than 50 years in the treatment of leukemia and lymphomas, and this treatment is commonly known as the bone marrow transplantation, but today hematopoietic stem cells, derived from umbilical cord blood and peripheral blood are more often used in the hematologic clinics of the world. At the same time, for the treatment of traumatic brain and spinal cord injuries, the stimulation of fractures and chronic wounds healing the mesenchymal stem cells are more preferred, being the precursors of the connective tissue. Mesenchymal stem cells are found in big quantity in fatty tissue, placenta, umbilical cord blood, amniotic fluid. Due to the immunosuppressive effects of mesenchymal stem cells, they are also used in the treatment of a variety of autoimmune diseases (multiple sclerosis, ulcerative colitis, Crohns disease, etc.), as well as post-transplantation complications (to prevent the rejection of the transplanted donor organ). For the treatment of cardiovascular diseases, including lower limbs ischemia, the umbilical cord blood is considered to be the most promising, as it contains a special kind of the endothelial progenitor stem cells, which can not be found in any other human tissue.

Cell therapy may be autologous (own cells are used) and allogeneic (donor cells are used). However, it is known that every nucleated cell in the human body has certain immunological characteristics (HLA-phenotype or immune passport), that is why the use of donor stem cells requires immunological compatibility. This fact determines the appropriateness of the banking of the own stem cells, frozen until the person is still young and healthy. In this aspect the human umbilical cord blood has undisputed medical and biological value as the source of several unique lines of stem cells. Collected in the first minutes of life, umbilical cord blood stem cells have the highest potential for proliferation (growth) and directed differentiation.

Stem cell therapy can be applied both intravenously like a drug, and directly into the damaged tissue. In recent years the method of intraosseous transplantation of cord blood stem cells is more widely used, contributing to the more rapid engraftment. Also a method of introducing stem cells directly into the coronary arteries (coronary heart disease, myocardial infarction) was introduced and it is called cellular cardiomyoplasty.

Cell therapy can be carried out both in monotherapy and complementary to the surgical or drug treatment.

Currently stem cells are successfully used in the treatment of about 100 serious diseases, and in some cases this is the only effective treatment.

Read the original:
Cell therapy - Institute of Cell Therapy - ...

Sarthak - Autologous Bone Marrow Cell Transplantation in CP with Sensory Neural Deafness
stem cell india, stem cell therapy india, stem cell in india, stem cell therapy in india, india stem cell, india stem cell therapy.

By: Stem Cell India

Read more:
Sarthak - Autologous Bone Marrow Cell Transplantation in CP with Sensory Neural Deafness - Video

Stem Cell Indonesia | Stem Cell Therapy | 0818 09055022
Stem Cell Indonesia Stem Cell Therapy Info: http://www.fullofblessings.jeunesseglobal.com 2A9F978E / +62818 09055022.

By: Stem Cell Indonesia

See the article here:
Stem Cell Indonesia | Stem Cell Therapy | 0818 09055022 - Video

Basic Evaluation Before PRP and Stem Cell Therapy in Osteoarthritis Knee
stem cell india, stem cell therapy india, stem cell in india, stem cell therapy in india, india stem cell, india stem cell therapy.

By: Stem Cell India

More:
Basic Evaluation Before PRP and Stem Cell Therapy in Osteoarthritis Knee - Video